0.06
-0.0099(-15.23%)
Currency In USD
| Previous Close | 0.07 |
| Open | 0.06 |
| Day High | 0.07 |
| Day Low | 0.06 |
| 52-Week High | 66 |
| 52-Week Low | 0.05 |
| Volume | 6,554 |
| Average Volume | 4.75M |
| Market Cap | 604,794 |
| PE | 0 |
| EPS | -81.37 |
| Moving Average 50 Days | 0.34 |
| Moving Average 200 Days | 19.12 |
| Change | -0.01 |
If you invested $1000 in Hepion Pharmaceuticals, Inc. (HEPA) 10 years ago, it would be worth $0 as of June 01, 2025 at a share price of $0.055. Whereas If you bought $1000 worth of Hepion Pharmaceuticals, Inc. (HEPA) shares 5 years ago, it would be worth $0.03 as of June 01, 2025 at a share price of $0.055.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq
GlobeNewswire Inc.
May 12, 2025 8:30 PM GMT
MORRISTOWN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HC
Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC
GlobeNewswire Inc.
May 07, 2025 12:30 PM GMT
MORRISTOWN, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company that had been developing a treatment for non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HC
Hepion Pharmaceuticals Announces Reverse Stock Split
GlobeNewswire Inc.
Mar 14, 2025 12:30 PM GMT
Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage biopharmaceutical company that has been developing a treat